Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01VWD
|
|||
| Former ID |
DIB014671
|
|||
| Drug Name |
HTI-101
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Phase 2 | [1] | |
| Company |
Hemodynamic Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Enzyme unspecific (Enz) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Hemodynamic Therapeutics. | |||
| REF 2 | Halozyme Therapeutics Announces New Studies From HTI-101 Presented at Proteoglycan Research Conference. Halozyme Therapeutics. JULY 12, 2006. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.